Lonza Group AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.
Compared to FY2019, FDA data show agency inspections of OTC and Rx drug manufacturing facilities in FY2020 fell 60%. As pandemic continues in FY2021, inspection rate will remain depressed, and it remains unclear how the agency will reduce the backlog without resorting to remotely conducted inspections.
FY2020 review highlights drop in inspections, preparations for growing backlog, and pandemic test of Janet Woodcock’s 21st Century proposition – developments that will likely reverberate in the years ahead.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.